Skip to main content
Erschienen in:

06.12.2022 | Speicheldrüsenkarzinom | Leitthema

Panelsequenzierung in der Kopf-Hals-Onkologie am Beispiel von sinunasalen und Speicheldrüsenmalignomen

verfasst von: Prof. Dr. med. Abbas Agaimy, Sarina K. Müller

Erschienen in: Die Onkologie | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Infolge der zunehmend eingeführten innovativen molekularen Technologien erlebte die Pathologie der Speicheldrüsenkarzinome und der sinunasalen Karzinome in den letzten 2 Jahrzehnten eine revolutionierende dynamische Evolution.

Ziel

Mit der Einführung der molekularen Tumorboards in der Kopf-Hals-Pathoonkologie stellt sich zunehmend die Frage, welche Entitäten/Patienten für eine Panelsequenzierung in Betracht kommen. Das Ziel der vorliegenden Übersichtsarbeit liegt darin, diese Frage im Hinblick auf aktuelle Entwicklungen und in Bezug auf die aktuelle Klassifikation der Weltgesundheitsorganisation (WHO) zu erörtern.

Material und Methoden

Diese Übersicht basiert auf einer selektiven Literaturrecherche (PubMed) zu den Themen Speicheldrüsenmalignome, Sinunasalkarzinome und zielgerichtete Therapien wie auch auf eigenen Daten und Beobachtungen der Autoren.

Ergebnisse und Schlussfolgerung

Durch neue Entwicklungen bei der Differenzialdiagnostik von Malignomen der Speicheldrüsen und Sinunasalorgane wurden manche alten Konzeptionen neu definiert, neue Konzepte eingeführt und manche alten Entitäten molekular besser definiert. Diese Entwicklungen haben sowohl Einfluss auf die Diagnostik (sie ermöglichen eine verfeinerte, oft molekular basierte Klassifikation bislang unklassifizierter Neoplasien) als auch auf die Therapie (sie ermöglichen eine bessere histologieorientierte Therapiestratifikation und gelten z. T. als Biomarker für zielgerichtete Therapien).
Literatur
2.
Zurück zum Zitat Skálová A, Stenman G, Simpson RHW, Hellquist H, Slouka D, Svoboda T, Bishop JA, Hunt JL, Nibu KI, Rinaldo A, Vander Poorten V, Devaney KO, Steiner P, Ferlito A (2018) The role of molecular testing in the differential diagnosis of salivary gland carcinomas. Am J Surg Pathol 42(2):e11–e27CrossRef Skálová A, Stenman G, Simpson RHW, Hellquist H, Slouka D, Svoboda T, Bishop JA, Hunt JL, Nibu KI, Rinaldo A, Vander Poorten V, Devaney KO, Steiner P, Ferlito A (2018) The role of molecular testing in the differential diagnosis of salivary gland carcinomas. Am J Surg Pathol 42(2):e11–e27CrossRef
3.
Zurück zum Zitat Skálová A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, Starek I, Geierova M, Simpson RH, Passador-Santos F, Ryska A, Leivo I, Kinkor Z, Michal M (2010) Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34(5):599–608CrossRef Skálová A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, Starek I, Geierova M, Simpson RH, Passador-Santos F, Ryska A, Leivo I, Kinkor Z, Michal M (2010) Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34(5):599–608CrossRef
4.
Zurück zum Zitat Skalova A, Vanecek T, Martinek P, Weinreb I, Stevens TM, Simpson RHW, Hyrcza M, Rupp NJ, Baneckova M, Michal M Jr, Slouka D, Svoboda T, Metelkova A, Etebarian A, Pavelka J, Potts SJ, Christiansen J, Steiner P, Michal M (2018) Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET Translocation: report of 10 cases. Am J Surg Pathol 42(2):234–246CrossRef Skalova A, Vanecek T, Martinek P, Weinreb I, Stevens TM, Simpson RHW, Hyrcza M, Rupp NJ, Baneckova M, Michal M Jr, Slouka D, Svoboda T, Metelkova A, Etebarian A, Pavelka J, Potts SJ, Christiansen J, Steiner P, Michal M (2018) Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET Translocation: report of 10 cases. Am J Surg Pathol 42(2):234–246CrossRef
5.
Zurück zum Zitat Chiosea SI, Williams L, Griffith CC et al (2015) Molecular characterization of apocrine salivary duct carcinoma. Am J Surg Pathol 39:744–752CrossRef Chiosea SI, Williams L, Griffith CC et al (2015) Molecular characterization of apocrine salivary duct carcinoma. Am J Surg Pathol 39:744–752CrossRef
6.
Zurück zum Zitat Kleinsasser O, Klein HJ, Hübner G (1968) Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 192(1):100–105CrossRef Kleinsasser O, Klein HJ, Hübner G (1968) Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 192(1):100–105CrossRef
7.
Zurück zum Zitat Di Palma S, Simpson RH, Marchio C et al (2012) Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Histopathology 61:629–643CrossRef Di Palma S, Simpson RH, Marchio C et al (2012) Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Histopathology 61:629–643CrossRef
8.
Zurück zum Zitat Skalova A, Leivo I, Hellquist H, Agaimy A, Simpson RHW, Stenman G, Vander Poorten V, Bishop JA, Franchi A, Hernandez-Prera JC, Slouka D, Willems SM, Olsen KD, Ferlito A (2021) High-grade transformation/dedifferentiation in salivary gland carcinomas: occurrence across subtypes and clinical significance. Adv Anat Pathol 28(3):107–118CrossRef Skalova A, Leivo I, Hellquist H, Agaimy A, Simpson RHW, Stenman G, Vander Poorten V, Bishop JA, Franchi A, Hernandez-Prera JC, Slouka D, Willems SM, Olsen KD, Ferlito A (2021) High-grade transformation/dedifferentiation in salivary gland carcinomas: occurrence across subtypes and clinical significance. Adv Anat Pathol 28(3):107–118CrossRef
9.
Zurück zum Zitat Todorovic E, Dickson BC, Weinreb I (2020) Salivary gland cancer in the era of routine next-generation sequencing. Head Neck Pathol 14:311–320CrossRef Todorovic E, Dickson BC, Weinreb I (2020) Salivary gland cancer in the era of routine next-generation sequencing. Head Neck Pathol 14:311–320CrossRef
10.
Zurück zum Zitat Agaimy A, Baněčková M, Ihrler S, Mueller SK, Franchi A, Hartmann A, Stoehr R, Skálová A (2021) ALK rearrangements characterize 2 distinct types of salivary gland carcinomas: clinicopathologic and molecular analysis of 4 cases and literature review. Am J Surg Pathol 45(9):1166–1178CrossRef Agaimy A, Baněčková M, Ihrler S, Mueller SK, Franchi A, Hartmann A, Stoehr R, Skálová A (2021) ALK rearrangements characterize 2 distinct types of salivary gland carcinomas: clinicopathologic and molecular analysis of 4 cases and literature review. Am J Surg Pathol 45(9):1166–1178CrossRef
11.
Zurück zum Zitat Rooper LM, Mansour M, Yonescu R, Oliai BR, Bishop JA, Westra WH (2021) The decline of salivary adenocarcinoma not otherwise specified as a tumor entity: reclassification using contemporary immunohistochemical profiling and diagnostic criteria. Am J Surg Pathol 45(6):753–764CrossRef Rooper LM, Mansour M, Yonescu R, Oliai BR, Bishop JA, Westra WH (2021) The decline of salivary adenocarcinoma not otherwise specified as a tumor entity: reclassification using contemporary immunohistochemical profiling and diagnostic criteria. Am J Surg Pathol 45(6):753–764CrossRef
12.
Zurück zum Zitat Girelli L, Locati L, Galeone C et al (2017) Lung metastasectomy in adenoid cystic cancer: is it worth it? Oral Oncol 65:114–118CrossRef Girelli L, Locati L, Galeone C et al (2017) Lung metastasectomy in adenoid cystic cancer: is it worth it? Oral Oncol 65:114–118CrossRef
13.
Zurück zum Zitat Sahara S, Herzog A, Nör J (2021) Systemic therapies for salivary gland adenoid cystic carcinoma. Am J Cancer Res 11(9):4092–4110 Sahara S, Herzog A, Nör J (2021) Systemic therapies for salivary gland adenoid cystic carcinoma. Am J Cancer Res 11(9):4092–4110
14.
Zurück zum Zitat Ghosal N, Mais K, Shenjere P et al (2011) Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. Br J Oral Maxillofac Surg 49(7):510–515CrossRef Ghosal N, Mais K, Shenjere P et al (2011) Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. Br J Oral Maxillofac Surg 49(7):510–515CrossRef
15.
Zurück zum Zitat Wong S, Karrison T, Hayes D et al (2016) Phase II trial of dasatinib for recurrent or metastatic c‑KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol 27(2):318–323CrossRef Wong S, Karrison T, Hayes D et al (2016) Phase II trial of dasatinib for recurrent or metastatic c‑KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol 27(2):318–323CrossRef
16.
Zurück zum Zitat Rupa V, Jacob M, Mathews MS, Seshadri MS (2010) A prospective, randomised, placebocontrolled trial of postoperative oral steroid in allergic fungal sinusitis. Eur Arch Otorhinolaryngol 267(2):233–238CrossRef Rupa V, Jacob M, Mathews MS, Seshadri MS (2010) A prospective, randomised, placebocontrolled trial of postoperative oral steroid in allergic fungal sinusitis. Eur Arch Otorhinolaryngol 267(2):233–238CrossRef
17.
Zurück zum Zitat Agulnik M, Cohen E, Cohen R et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25:3978–3984CrossRef Agulnik M, Cohen E, Cohen R et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25:3978–3984CrossRef
18.
Zurück zum Zitat Locati L, Bossi P, Perrone F et al (2009) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45:574–578CrossRef Locati L, Bossi P, Perrone F et al (2009) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45:574–578CrossRef
19.
Zurück zum Zitat Keam B, Kim S, Shin S et al (2015) Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer 121:2612–2617CrossRef Keam B, Kim S, Shin S et al (2015) Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer 121:2612–2617CrossRef
20.
Zurück zum Zitat Dillon P, Petroni G, Horton B et al (2017) A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res 23:4138–4145CrossRef Dillon P, Petroni G, Horton B et al (2017) A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res 23:4138–4145CrossRef
21.
Zurück zum Zitat Kim Y, Lee S, Lee J et al (1964) Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean cancer study group HN14-01). Cancer 123:1958–1964CrossRef Kim Y, Lee S, Lee J et al (1964) Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean cancer study group HN14-01). Cancer 123:1958–1964CrossRef
22.
Zurück zum Zitat Chau N, Hotte S, Chen E et al (2012) A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 23:1562–1570CrossRef Chau N, Hotte S, Chen E et al (2012) A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 23:1562–1570CrossRef
23.
Zurück zum Zitat Ho A, Sherman E, Baxi S et al (2016) Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma. J Clin Oncol 34:6069–6069CrossRef Ho A, Sherman E, Baxi S et al (2016) Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma. J Clin Oncol 34:6069–6069CrossRef
24.
Zurück zum Zitat Tchekmedyian V, Sherman E, Dunn L et al (2019) Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol 37:1529–1537CrossRef Tchekmedyian V, Sherman E, Dunn L et al (2019) Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol 37:1529–1537CrossRef
25.
Zurück zum Zitat Locati L, Galbiati D, Calareso G et al (2020) Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life. Cancer 126:1888–1894CrossRef Locati L, Galbiati D, Calareso G et al (2020) Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life. Cancer 126:1888–1894CrossRef
26.
Zurück zum Zitat Locati L, Cavalieri S, Bergamin C et al (2019) Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. Head Neck 41(10):3670–3676CrossRef Locati L, Cavalieri S, Bergamin C et al (2019) Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. Head Neck 41(10):3670–3676CrossRef
27.
Zurück zum Zitat Ho A, Dunn L, Sherman E et al (2016) A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol 27:1902–1908CrossRef Ho A, Dunn L, Sherman E et al (2016) A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol 27:1902–1908CrossRef
28.
Zurück zum Zitat Locati L, Perrone F, Cortelazzi B et al (2016) A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact. Eur J Cancer 69:158–165CrossRef Locati L, Perrone F, Cortelazzi B et al (2016) A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact. Eur J Cancer 69:158–165CrossRef
29.
Zurück zum Zitat Thomson D, Silva P, Denton K et al (2015) Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head Neck 37:182–187CrossRef Thomson D, Silva P, Denton K et al (2015) Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head Neck 37:182–187CrossRef
30.
Zurück zum Zitat Licitra L, Marchini S, Spinazzè S et al (1991) Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 68(9):1874–1877CrossRef Licitra L, Marchini S, Spinazzè S et al (1991) Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 68(9):1874–1877CrossRef
31.
Zurück zum Zitat Licitra L, Cavina R, Grandi C et al (1996) Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 7:640–642CrossRef Licitra L, Cavina R, Grandi C et al (1996) Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 7:640–642CrossRef
32.
Zurück zum Zitat Ahn M, Yoon J (2017) Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells. J Oral Pathol Med 46(4):276–283CrossRef Ahn M, Yoon J (2017) Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells. J Oral Pathol Med 46(4):276–283CrossRef
33.
Zurück zum Zitat Ettl T, Schwarz-Furlan S, Haubner F et al (2012) The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol 48(9):822–830CrossRef Ettl T, Schwarz-Furlan S, Haubner F et al (2012) The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol 48(9):822–830CrossRef
34.
Zurück zum Zitat Thorpe L, Schrock A, Erlich R et al (2017) Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature. Head Neck 39(3):E40–44CrossRef Thorpe L, Schrock A, Erlich R et al (2017) Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature. Head Neck 39(3):E40–44CrossRef
35.
Zurück zum Zitat De Block K, Vander Poorten V, Dormaar T et al (2016) Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients. Acta Clin Belg 71(6):383–388CrossRef De Block K, Vander Poorten V, Dormaar T et al (2016) Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients. Acta Clin Belg 71(6):383–388CrossRef
36.
Zurück zum Zitat Takahashi H, Masubuchi T, Fushimi C et al (2016) Trastuzumab and docetaxel for HER‑2 positive unresectable salivary gland carcinoma: updated results of a phase II trial. Am Head Neck Soc, Seattle, WA, S 16–20 (Abstr 9th Int Conf Head Neck Cancer) Takahashi H, Masubuchi T, Fushimi C et al (2016) Trastuzumab and docetaxel for HER‑2 positive unresectable salivary gland carcinoma: updated results of a phase II trial. Am Head Neck Soc, Seattle, WA, S 16–20 (Abstr 9th Int Conf Head Neck Cancer)
37.
Zurück zum Zitat Kurzrock R, Meric-Bernstam F, Hurwitz H et al (2017) Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: interim data from MyPathway. J Clin Oncol 35(15):6086CrossRef Kurzrock R, Meric-Bernstam F, Hurwitz H et al (2017) Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: interim data from MyPathway. J Clin Oncol 35(15):6086CrossRef
38.
Zurück zum Zitat Schmitt N, Kang H, Sharma A (2017) Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol 74:40–48CrossRef Schmitt N, Kang H, Sharma A (2017) Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol 74:40–48CrossRef
40.
Zurück zum Zitat Wagner F, Greim R, Krebs K, Luebben F, Dimmler A (2021) Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report. Diagn Pathol 16(1):73CrossRef Wagner F, Greim R, Krebs K, Luebben F, Dimmler A (2021) Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report. Diagn Pathol 16(1):73CrossRef
42.
Zurück zum Zitat Mahmood U, Bang A, Chen YH et al (2021) A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma. int J Radiat Oncol Biol Phys 109:134–144CrossRef Mahmood U, Bang A, Chen YH et al (2021) A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma. int J Radiat Oncol Biol Phys 109:134–144CrossRef
43.
Zurück zum Zitat Cohen R, Delord J, Doi T et al (2018) Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol 41(11):1083–1088CrossRef Cohen R, Delord J, Doi T et al (2018) Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol 41(11):1083–1088CrossRef
44.
Zurück zum Zitat Villeneuve L, Souza I, Tolentino FDS, Ferrarotto R, Schvartsman G (2020) Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease. Front Oncol 10:580141CrossRef Villeneuve L, Souza I, Tolentino FDS, Ferrarotto R, Schvartsman G (2020) Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease. Front Oncol 10:580141CrossRef
45.
Zurück zum Zitat van Boxtel W, Lütje S, van Engen-van Grunsven I et al (2020) 68 Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics 10(5):2273–2283CrossRef van Boxtel W, Lütje S, van Engen-van Grunsven I et al (2020) 68 Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics 10(5):2273–2283CrossRef
46.
Zurück zum Zitat Taverna C, Agaimy A, Franchi A (2022) Towards a molecular classification of sinonasal carcinomas: clinical implications and opportunities. Cancers (Basel) 14(6):1463CrossRef Taverna C, Agaimy A, Franchi A (2022) Towards a molecular classification of sinonasal carcinomas: clinical implications and opportunities. Cancers (Basel) 14(6):1463CrossRef
47.
Zurück zum Zitat Agaimy A, Franchi A, Lund VJ, Skálová A, Bishop JA, Triantafyllou A, Andreasen S, Gnepp DR, Hellquist H, Thompson LDR, Rinaldo A, Ferlito A (2020) Sinonasal undifferentiated carcinoma (SNUC): from an entity to morphologic pattern and back again—a historical perspective. Adv Anat Pathol 27(2):51–60CrossRef Agaimy A, Franchi A, Lund VJ, Skálová A, Bishop JA, Triantafyllou A, Andreasen S, Gnepp DR, Hellquist H, Thompson LDR, Rinaldo A, Ferlito A (2020) Sinonasal undifferentiated carcinoma (SNUC): from an entity to morphologic pattern and back again—a historical perspective. Adv Anat Pathol 27(2):51–60CrossRef
48.
Zurück zum Zitat Stelow EB, French CA (2009) Carcinomas of the upper aerodigestive tract with rearrangement of the nuclear protein of the testis (NUT) gene (NUT midline carcinomas). Adv Anat Pathol 16:92–96CrossRef Stelow EB, French CA (2009) Carcinomas of the upper aerodigestive tract with rearrangement of the nuclear protein of the testis (NUT) gene (NUT midline carcinomas). Adv Anat Pathol 16:92–96CrossRef
49.
Zurück zum Zitat Agaimy A (2022) Proceedings of the North American society of head and neck pathology, Los Angeles, CA, march 20, 2022: SWI/SNF-deficient sinonasal neoplasms: an overview. Head Neck Pathol 16(1):168–178CrossRef Agaimy A (2022) Proceedings of the North American society of head and neck pathology, Los Angeles, CA, march 20, 2022: SWI/SNF-deficient sinonasal neoplasms: an overview. Head Neck Pathol 16(1):168–178CrossRef
50.
Zurück zum Zitat Rooper LM, Uddin N, Gagan J, Brosens LAA, Magliocca KR, Edgar MA, Thompson LDR, Agaimy A, Bishop JA (2020) Recurrent loss of SMARCA4 in sinonasal teratocarcinosarcoma. Am J Surg Pathol 44(10):1331–1339CrossRef Rooper LM, Uddin N, Gagan J, Brosens LAA, Magliocca KR, Edgar MA, Thompson LDR, Agaimy A, Bishop JA (2020) Recurrent loss of SMARCA4 in sinonasal teratocarcinosarcoma. Am J Surg Pathol 44(10):1331–1339CrossRef
51.
Zurück zum Zitat Bishop JA, Andreasen S, Hang JF, Bullock MJ, Chen TY, Franchi A, Garcia JJ, Gnepp DR, Gomez-Fernandez CR, Ihrler S, Kuo YJ, Lewis JS Jr, Magliocca KR, Pambuccian S, Sandison A, Uro-Coste E, Stelow E, Kiss K, Westra WH (2017) HPV-related multiphenotypic sinonasal carcinoma: an expanded series of 49 cases of the tumor formerly known as HPV-related carcinoma with adenoid cystic carcinoma-like features. Am J Surg Pathol 41(12):1690–1701CrossRef Bishop JA, Andreasen S, Hang JF, Bullock MJ, Chen TY, Franchi A, Garcia JJ, Gnepp DR, Gomez-Fernandez CR, Ihrler S, Kuo YJ, Lewis JS Jr, Magliocca KR, Pambuccian S, Sandison A, Uro-Coste E, Stelow E, Kiss K, Westra WH (2017) HPV-related multiphenotypic sinonasal carcinoma: an expanded series of 49 cases of the tumor formerly known as HPV-related carcinoma with adenoid cystic carcinoma-like features. Am J Surg Pathol 41(12):1690–1701CrossRef
52.
Zurück zum Zitat Thompson LDR, Jo VY, Agaimy A, Llombart-Bosch A, Morales GN, Machado I, Flucke U, Wakely PE Jr, Miettinen M, Bishop JA (2018) Sinonasal tract alveolar rhabdomyosarcoma in adults: a clinicopathologic and immunophenotypic study of fifty-two cases with emphasis on epithelial Immunoreactivity. Head Neck Pathol 12(2):181–192CrossRef Thompson LDR, Jo VY, Agaimy A, Llombart-Bosch A, Morales GN, Machado I, Flucke U, Wakely PE Jr, Miettinen M, Bishop JA (2018) Sinonasal tract alveolar rhabdomyosarcoma in adults: a clinicopathologic and immunophenotypic study of fifty-two cases with emphasis on epithelial Immunoreactivity. Head Neck Pathol 12(2):181–192CrossRef
53.
Zurück zum Zitat Rooper LM, Bishop JA (2020) Soft tissue special issue: adamantinoma-like ewing sarcoma of the head and neck: a practical review of a challenging emerging entity. Head Neck Pathol 14(1):59–69CrossRef Rooper LM, Bishop JA (2020) Soft tissue special issue: adamantinoma-like ewing sarcoma of the head and neck: a practical review of a challenging emerging entity. Head Neck Pathol 14(1):59–69CrossRef
54.
Zurück zum Zitat Agaimy A, Fonseca I, Martins C, Thway K, Barrette R, Harrington KJ, Hartmann A, French CA, Fisher C (2018) NUT carcinoma of the salivary glands: clinicopathologic and molecular analysis of 3 cases and a survey of NUT expression in salivary gland carcinomas. Am J Surg Pathol 42:877–884CrossRef Agaimy A, Fonseca I, Martins C, Thway K, Barrette R, Harrington KJ, Hartmann A, French CA, Fisher C (2018) NUT carcinoma of the salivary glands: clinicopathologic and molecular analysis of 3 cases and a survey of NUT expression in salivary gland carcinomas. Am J Surg Pathol 42:877–884CrossRef
55.
Zurück zum Zitat French CA (2013) The importance of diagnosing NUT midline carcinoma. Head Neck Pathol 7:11CrossRef French CA (2013) The importance of diagnosing NUT midline carcinoma. Head Neck Pathol 7:11CrossRef
56.
Zurück zum Zitat Glöss S, Jurmeister P, Thieme A, Schmid S, Cai WY, Serrette RN, Perner S, Ribbat-Idel J, Pagenstecher A, Bläker H, Keber U, Stadelmann C, Zechel S, Johann PD, Hasselblatt M, Paulus W, Thomas C, Dohmen H, Baumhoer D, Frank S, Agaimy A, Schüller U, Vasudevaraja V, Snuderl M, Liu CZ, Pfister DG, Jungbluth AA, Ghossein RA, Xu B, Capper D, Dogan S (2021) IDH2 R172 mutations across poorly differentiated sinonasal tract malignancies: forty molecularly homogenous and histologically variable cases with favorable outcome. Am J Surg Pathol 45(9):1190–1204CrossRef Glöss S, Jurmeister P, Thieme A, Schmid S, Cai WY, Serrette RN, Perner S, Ribbat-Idel J, Pagenstecher A, Bläker H, Keber U, Stadelmann C, Zechel S, Johann PD, Hasselblatt M, Paulus W, Thomas C, Dohmen H, Baumhoer D, Frank S, Agaimy A, Schüller U, Vasudevaraja V, Snuderl M, Liu CZ, Pfister DG, Jungbluth AA, Ghossein RA, Xu B, Capper D, Dogan S (2021) IDH2 R172 mutations across poorly differentiated sinonasal tract malignancies: forty molecularly homogenous and histologically variable cases with favorable outcome. Am J Surg Pathol 45(9):1190–1204CrossRef
57.
Zurück zum Zitat Amit M, Abdelmeguid A, Watcherporn T et al (2019) Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentated carcinoma. J Clin Oncol 37(6):504–512CrossRef Amit M, Abdelmeguid A, Watcherporn T et al (2019) Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentated carcinoma. J Clin Oncol 37(6):504–512CrossRef
58.
Zurück zum Zitat Lilly G, Geltzeiler M (2021) Induction chemotherapy for orbit preservation in sinonasal squamous cell carcinoma. J Neurol Surg Rep 82(3):e36–e37CrossRef Lilly G, Geltzeiler M (2021) Induction chemotherapy for orbit preservation in sinonasal squamous cell carcinoma. J Neurol Surg Rep 82(3):e36–e37CrossRef
59.
Zurück zum Zitat Park J, Faquin W, Durbeck J, Fadena D (2020) Immune checkpoint inhibitors in sinonasal squamous cell carcinoma. Oral Oncol 109:104776CrossRef Park J, Faquin W, Durbeck J, Fadena D (2020) Immune checkpoint inhibitors in sinonasal squamous cell carcinoma. Oral Oncol 109:104776CrossRef
60.
Zurück zum Zitat Adnan A, Basu S (2020) Combined 177 Lu-DOTATATE peptide receptor radionuclide therapy and platinum-based chemotherapy in recurrent, metastatic sinonasal neuroendocrine carcinoma: a promising therapeutic option. J Nucl Med Technol 48(3):292–294CrossRef Adnan A, Basu S (2020) Combined 177 Lu-DOTATATE peptide receptor radionuclide therapy and platinum-based chemotherapy in recurrent, metastatic sinonasal neuroendocrine carcinoma: a promising therapeutic option. J Nucl Med Technol 48(3):292–294CrossRef
62.
Zurück zum Zitat Wanior M, Krämer A, Knapp S, Joerger AC (2021) Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy. Oncogene 40(21):3637–3654CrossRef Wanior M, Krämer A, Knapp S, Joerger AC (2021) Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy. Oncogene 40(21):3637–3654CrossRef
63.
Zurück zum Zitat Xue Y, Meehan B, Fu Z, Wang XQD, Fiset PO, Rieker R, Levins C, Kong T, Zhu X, Morin G, Skerritt L, Herpel E, Venneti S, Martinez D, Judkins AR, Jung S, Camilleri-Broet S, Gonzalez AV, Guiot MC, Lockwood WW, Spicer JD, Agaimy A, Pastor WA, Dostie J, Rak J, Foulkes WD, Huang S (2019) SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nat Commun 10(1):557CrossRef Xue Y, Meehan B, Fu Z, Wang XQD, Fiset PO, Rieker R, Levins C, Kong T, Zhu X, Morin G, Skerritt L, Herpel E, Venneti S, Martinez D, Judkins AR, Jung S, Camilleri-Broet S, Gonzalez AV, Guiot MC, Lockwood WW, Spicer JD, Agaimy A, Pastor WA, Dostie J, Rak J, Foulkes WD, Huang S (2019) SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nat Commun 10(1):557CrossRef
Metadaten
Titel
Panelsequenzierung in der Kopf-Hals-Onkologie am Beispiel von sinunasalen und Speicheldrüsenmalignomen
verfasst von
Prof. Dr. med. Abbas Agaimy
Sarina K. Müller
Publikationsdatum
06.12.2022
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 1/2023
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-022-01270-0

Weitere Artikel der Ausgabe 1/2023

Die Onkologie 1/2023 Zur Ausgabe

Passend zum Thema

ANZEIGE

AGO-Leitlinie 2024: Update zu CDK4 & 6 Inhibitoren

Die Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) hat am 02. März 2024 ihre aktualisierten Empfehlungen präsentiert.[1,2] Welchen Stellenwert CDK4 & 6 Inhibitoren in der Therapie des Hormonrezeptor-positiven (HR+), HER2-negativen (HER2-) Mammakarzinoms haben, erfahren Sie hier im Update.

ANZEIGE

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

In der MONARCH-3-Studie erhielten Patientinnen mit fortgeschrittenem HR+, HER2- Brustkrebs Abemaciclib [1,a] in Kombination mit nicht-steroidalem Aromatasehemmer (nsAI). Die finalen Daten bestätigen den in früheren Analysen beobachteten Unterschied zugunsten der Kombinationstherapie. [2] Details dazu vom SABCS 2023.

ANZEIGE

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom

Es erwarten Sie praxisrelevante Patientenfälle, kompakte Studiendarstellungen, informative Experteninterviews sowie weitere spannende Inhalte rund um das HR+, HER2- Mammakarzinom.